Phio Pharmaceuticals
Phio’s proprietary RNA interference (RNAi) technology makes immune cells more effective in killing tumor cells.
Launch date
Employees
Market cap
CAD3.9m
Enterprise valuation
(CAD8m) (Public information from Sep 2024)
Share price
$3.55 PHIO
Marlborough Massachusetts (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | 50.0m | 75.0m |
% growth | - | - | - | - | - | - | 50 % |
EBITDA | - | (8.7m) | (13.5m) | (11.5m) | (10.4m) | - | - |
Profit | - | (8.8m) | (13.3m) | (11.5m) | (10.8m) | (9.6m) | 47.7m |
% profit margin | - | - | - | - | - | (19 %) | 64 % |
EV / revenue | - | - | - | - | - | 0.1x | 0.0x |
EV / EBITDA | - | -1.8x | -1.0x | -0.4x | -0.2x | - | - |
R&D budget | - | 4.4m | 8.9m | 7.0m | 6.3m | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | $300k | Grant | |
* | N/A | $16.4m | Private Placement VC |
* | $20.0m | Post IPO Equity | |
$10.4m | Post IPO Equity | ||
* | N/A | $4.9m | Post IPO Equity |
N/A | $15.0m | Post IPO Equity | |
* | N/A | $1.0m | Post IPO Equity |
N/A | $1.7m | Post IPO Equity | |
* | N/A | $8.0m | Post IPO Equity |
* | N/A | $14.0m | Private Placement VC |
* | N/A | $7.7m | Post IPO Equity |
* | N/A | $2.0m | Post IPO Equity |
* | N/A | $4.0m | Post IPO Equity |
* | N/A | $2.8m | Post IPO Equity |
* | $621k | Post IPO Equity | |
* | N/A | $3.1m | Post IPO Equity |
Total Funding | CAD41.9m |